CMS continues NTAP for T2's bacteria panel in FY 2021

By staff writers

September 23, 2020 -- The U.S. Centers for Medicare and Medicaid Services (CMS) will continue the new technology add-on payment (NTAP) for T2 Biosystems' T2Bacteria panel for the 2021 fiscal year.

The extension allows U.S. hospitals treating sepsis patients who are covered by Medicare to remain eligible for an NTAP of $97.50 for the T2Bacteria panel. This payment covers 65% of the average cost of the test panel, which detects pathogens that cause sepsis, for eligible patients, according to the company.

T2's COVID-19 molecular test gets FDA nod
The U.S. Food and Drug Administration (FDA) has granted an emergency use authorization to T2 Biosystems for its COVID-19 molecular diagnostic test, T2SARS-CoV-2...
T2 Biosystems to launch COVID-19 test in the U.S.
T2 Biosystems announced it has completed the validation of its COVID-19 molecular diagnostic test and will distribute it commercially in the U.S.
T2 adds coronavirus test to panels, per health network deal
T2 Biosystems has signed a worldwide licensing agreement for a rapid test developed by New Jersey-based Hackensack Meridian Health for SARS-CoV-2.
T2 Biosystems recruits Chembio's John Sperzel as new CEO
T2 Biosystems has named John Sperzel as its new president and CEO. Sperzel most recently served as president and CEO of infectious disease point-of-care...
T2 Biosystems advances new tests through BARDA funding
T2 Biosystems is accelerating the development of new direct-from-blood tests through a milestone-based funding contract with the U.S. Biomedical Advanced...

Copyright © 2020

Last Updated np 9/29/2020 4:57:31 PM